Literature DB >> 21253969

Expression of Toll-like receptor 4, CD14, and NF-κB in Chinese patients with ulcerative colitis.

Zhen-hai Yu1, Fei Huang, Ning Xu, Dong-mei Zhao, Feng-ai Hu, Jiao Liu, Hong-fu Liu.   

Abstract

This study elucidates the significance of Toll-like receptor 4 (TLR4), CD14, and nuclear factor (NF)-κB on the pathogenesis of ulcerative colitis (UC). Colonic biopsy specimens were collected from active UC and controls. The expression of TLR4, CD14, and NF-κBp 65 was analyzed by immunohistochemistry (IHC) and reverse-transcription polymerase chain reaction (RT-PCR). In UC, disease activity index (DAI) and pathological grade were classified according to the Powell-Tuck grade system and Truelove-Richards system, respectively. Fifty-six UC cases and 56 controls entered the investigation. IHC and RT-PCR revealed a significant increase of TLR4, CD14, and NF-κBp 65 antigen expression in colonic mucosa of UC compared with colonic mucosa of controls (p < .001). In UC, TLR4, CD14, and NF-κBp 65 expression were positively related to DAI (r = .873, p < .001; r = .576, p < .001; r = .747, p < .001 receptively). NF-κBp65 significantly correlated with TLR4 and CD14 (r = .669, p < .001; r = .576, p < .001, receptively). TLR4, CD14, and NF-κBp65 were positively related to pathological classification in UC (p < .01). Thus, TLR4, CD14, and NF-κBp65 were upregulated significantly in UC, to an extent that reflects the degree of inflammation and thereby might contribute to the occurrence and development of UC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21253969     DOI: 10.1080/15321819.2010.538108

Source DB:  PubMed          Journal:  J Immunoassay Immunochem        ISSN: 1532-1819


  2 in total

Review 1.  Targeting NF-κB pathway for treating ulcerative colitis: comprehensive regulatory characteristics of Chinese medicines.

Authors:  Peng-De Lu; Yong-Hua Zhao
Journal:  Chin Med       Date:  2020-02-10       Impact factor: 5.455

2.  The Protection of Crocin Against Ulcerative Colitis and Colorectal Cancer via Suppression of NF-κB-Mediated Inflammation.

Authors:  Shanshan Teng; Jie Hao; Hui Bi; Congcong Li; Yongfeng Zhang; Yaqin Zhang; Weiwei Han; Di Wang
Journal:  Front Pharmacol       Date:  2021-03-18       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.